Search

Your search keyword '"Hawkes, Eliza A."' showing total 610 results
Start Over Author "Hawkes, Eliza A."
610 results on '"Hawkes, Eliza A."'

51. P1127: FINAL ANALYSIS OF AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP NHL29: A PHASE II STUDY OF IBRUTINIB, RITUXIMAB AND MINI-CHOP IN VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED DLBCL

Author

Verner, Emma, primary, Johnston, Amanda, additional, Pati, Nalini, additional, Hawkes, Eliza, additional, Peng Lee, Hui, additional, Cochrane, Tara, additional, Yoon Cheah, Chan, additional, Filshie, Robin, additional, Purtill, Duncan, additional, Sia, Hanlon, additional, Enjeti, Anoop K, additional, Brown, Christina, additional, Murphy, Nicholas, additional, Curnow, Jennifer, additional, Lee, Kenneth, additional, Gandhi, Maher, additional, Butcher, Belinda, additional, and Trotman, Judith, additional

Published
2023
Full Text
View/download PDF

52. PB2343: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS STANDARD OF CARE THERAPY IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (OLYMPIA-4)

Author

Hawkes, Eliza A., primary, Kim, Tae Min, additional, Namuduri, Manjusha, additional, Risal, Ashish, additional, Shen, Biyi, additional, Flink, Dina, additional, Zhu, Min, additional, Nolan, Siobhán, additional, Brouwer-Visser, Jurriaan, additional, Chaudhry, Aafia, additional, Ambati, Srikanth, additional, Mohamed, Hesham, additional, and Cho, Seok-Goo, additional

Published
2023
Full Text
View/download PDF

53. P1230: T CELL CD62L EXPRESSION FOLLOWING NIVOLUMAB THERAPY IS ASSOCIATED WITH LONG TERM RESPONSE TO RITUXIMAB-NIVOLUMAB IN TREATMENT NAÏVE FOLLICULAR LYMPHOMA: RESULTS FROM THE 1ST FLOR STUDY

Author

Koldej, Rachel, primary, Barraclough, Allison, additional, Ting Lee, Sze, additional, Morgan, Huw, additional, Holzwart, Nicholas, additional, Koshy, Minu, additional, Smith, Charmaine, additional, Chong, Geoff, additional, Gilbertson, Michael, additional, Keane, Colm, additional, Ting, Stephen, additional, Churilov, Leonid, additional, Ritchie, David, additional, and Hawkes, Eliza A., additional

Published
2023
Full Text
View/download PDF

55. P1193: POLATUZUMAB, BENDAMUSTINE & RITUXIMAB (POLA-BR) EFFICACY IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RRDLBCL) TRIAL-INELIGIBLE PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY

Author

Shaw, Briony, primary, Chung, Eliza, additional, Wellard, Cameron, additional, Yoo, Edward, additional, Bennett, Rory, additional, Birks, Callum, additional, Johnston, Anna, additional, Cheah, Chan, additional, Hamad, Nada, additional, Simpson, Jock, additional, Barraclough, Allison, additional, Ku, Matthew, additional, Viiala, Nicholas, additional, Ratnasingam, Sumita, additional, Armytage, Tasman, additional, Cochrane, Tara, additional, Chong, Geoff, additional, Lee, Denise, additional, Manos, Kate, additional, Keane, Colm, additional, Wallwork, Stephanie, additional, Opat, Stephen, additional, and Hawkes, Eliza A, additional

Published
2023
Full Text
View/download PDF

58. Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom.

Author

Minson, Adrian, Hamad, Nada, Di Ciaccio, Pietro, Talaulikar, Dipti, Ku, Matthew, Ratnasingam, Sumita, Cheah, Chan, Yannakou, Costas K., Bishton, Mark, Ng, Zi Yun, Agrawal, Shivam, McQuillan, Andrew, Johnston, Anna, Choong, Emily, Wong, Kimberly, McQuillan, James, Beekman, Ashley, Hawkes, Eliza, and Dickinson, Michael

Subjects
BISPECIFIC antibodies, CHIMERIC antigen receptors, NON-Hodgkin's lymphoma, OLDER patients
Abstract

Summary: Mantle cell lymphoma (MCL) is a B‐cell non‐Hodgkin lymphoma characterised by a heterogeneous clinical course. Patients can often receive sequential treatments, yet these typically yield diminishing periods of disease control, raising questions about optimal therapy sequencing. Novel agents, such as chimeric antigen receptor T‐cell therapies and bispecific antibodies, show promise in relapsed MCL, but are often reserved for later treatment lines, which may underserve patients with aggressive disease phenotypes who die early in the treatment journey. To assess the problem of patient attrition from lymphoma‐related death limiting sequential treatment, we performed a multicentre retrospective cohort analysis of 389 patients treated at Australian and UK centres over a 10‐year period. Deaths from MCL increased after each treatment line, with 7%, 23% and 26% of patients dying from uncontrolled MCL after first, second and third lines respectively. Patients with older age at diagnosis and early relapse after induction therapy were at particular risk of death after second‐line treatment. This limitation of sequential treatment by lymphoma‐related death provides support for the trial of novel therapies in earlier treatment lines, particularly in high‐risk patient populations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

60. Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance

Author

Barraclough, Allison, primary, England, James T., additional, Villa, Diego, additional, Wight, Joel, additional, Hapgood, Greg, additional, Conn, Jason, additional, Doo, Nicole Wong, additional, Li, Eric Wenlong, additional, Gilbertson, Michael, additional, Shaw, Briony, additional, Bishton, Mark J., additional, Saeed, Malik, additional, Ratnasingam, Sumita, additional, Abeyakoon, Chathuri, additional, Chong, Geoff, additional, Wai, Shin Hnin, additional, Ku, Matthew, additional, Lee, Hui-Peng, additional, Fleming, Kathryn, additional, Tam, Constantine, additional, Douglas, Genevieve, additional, Cheah, Chan Y., additional, Ng, Zi Yun, additional, Rolfe, Tukten, additional, Mills, Anthony K, additional, Hamad, Nada, additional, Cashman, Helen, additional, Gleeson, Mary, additional, Narayana, Manjunath, additional, and Hawkes, Eliza A., additional

Published
2023
Full Text
View/download PDF

61. Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Author

Opat, Stephen, primary, Tedeschi, Alessandra, additional, Hu, Bei, additional, Linton, Kim M, additional, McKay, Pamela, additional, Chan, Henry, additional, Jin, Jie, additional, Sun, Mingyuan, additional, Sobieraj-Teague, Magdalena, additional, Zinzani, Pier Luigi, additional, Browett, Peter, additional, Ke, Xiaoyan, additional, Portell, Craig A., additional, Thieblemont, Catherine, additional, Ardeshna, Kirit, additional, Bijou, Fontanet, additional, Walker, Patricia, additional, Hawkes, Eliza A., additional, Ho, Shir-Jing, additional, Zhou, Keshu, additional, Liang, Zhiyu, additional, Xu, Jianfeng, additional, Tankersley, Chris, additional, Delarue, Richard, additional, Co, Melannie, additional, and Trotman, Judith, additional

Published
2023
Full Text
View/download PDF

62. International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Author

Binkley, Michael S., primary, Flerlage, Jamie E., additional, Borchmann, Peter, additional, Fuchs, Michael, additional, Hartmann, Sylvia, additional, Eich, Hans Theodor, additional, Savage, Kerry J., additional, Lo, Andrea C., additional, Skinnider, Brian, additional, Akhtar, Saad, additional, Rauf, M. Shahzad, additional, Maghfoor, Irfan, additional, Pinnix, Chelsea, additional, Steiner, Raphael, additional, Milgrom, Sarah A., additional, Vega, Francisco, additional, Alomari, Mohammed, additional, Yang, Xiao-Yin, additional, Collins, Graham, additional, Advani, Ranjana H., additional, Metzger, Monika, additional, Dickinson, Michael, additional, Wirth, Andrew, additional, Tsang, Richard, additional, Prica, Anca, additional, Major, Ajay, additional, Smith, Sonali, additional, Hendrickson, Peter G., additional, Kelsey, Chris R., additional, Hopkins, David, additional, McKay, Pam, additional, Ng, Andrea, additional, Koenig, Julie, additional, Constine, Louis S., additional, Casulo, Carla, additional, Sakthivel, Gukan, additional, Baron, Jonathan, additional, Plastaras, John P., additional, Roberts, Kenneth B., additional, Gao, Sarah, additional, Al Kendi, Jalila, additional, Al Rahbi, Nasser, additional, Balogh, Alex, additional, Levis, Mario, additional, Ricardi, Umberto, additional, Sridhar, Akshay, additional, Torka, Pallawi, additional, Specht, Lena, additional, De Silva, Ravindu, additional, Shah, Nimish, additional, Pickard, Keir, additional, Osborne, Wendy, additional, Blazin, Lindsay J., additional, Henry, Michael, additional, Chang, Isabela, additional, Smith, Christine M., additional, Halperin, Daniel, additional, Miall, Fiona, additional, Brady, Jessica, additional, Mikhaeel, George, additional, Brennan, Bernadette, additional, Penn, Anthony, additional, Senchenko, Mariia Anatolevna, additional, Volchkov, Egor Vasilevich, additional, Reeves, Marie, additional, Hoppe, Bradford S., additional, Terezakis, Stephanie, additional, Talaulikar, Dipti, additional, Della Pepa, Roberta, additional, Picardi, Marco, additional, Kirova, Youlia, additional, Fergusson, Paige, additional, Northend, Michael, additional, Hawkes, Eliza, additional, Lee, Denise, additional, Wong Doo, Nicole, additional, Barraclough, Allison, additional, Opat, Stephen, additional, Cheah, Chan, additional, Salvaris, Ross, additional, Ku, Matthew, additional, Hamad, Nada, additional, Mutsando, Howard, additional, Tedjaseputra, Aditya, additional, Gilbertson, Michael, additional, Marconi, Tamara, additional, Viiala, Nicholas, additional, Palese, Monica, additional, Shankar, Ananth, additional, Maurer, Matthew J., additional, Natkunam, Yasodha, additional, Kelly, Kara M., additional, Eichenauer, Dennis A., additional, and Hoppe, Richard T., additional

Published
2023
Full Text
View/download PDF

63. Learnings from phosphatidylinositol 3‐kinase inhibitors in lymphoma—Moving to a model where less can be more.

Author

Martynchyk, Arina and Hawkes, Eliza A.

Subjects
*PHOSPHATIDYLINOSITOL 3-kinases, *MANTLE cell lymphoma, *LYMPHOMAS, *ANAPLASTIC lymphoma kinase, *DRUG development
Abstract

The role of Pi3K inhibitors in lymphoma is diminishing due to the adverse results from trials in indolent lymphoma, but is a one‐size‐fits‐all approach to drug development penalising some lymphoma subtypes and the newer generation of Pi3K inhibitors? The report by Soumerai et al. of zandelisib with zanubrutinib in follicular and mantle cell lymphoma is an important addition to the data. Commentary on: Soumerai et al. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas. Br J Haematol 2024;204:1762‐1770. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

64. High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.

Author

Lewis, Katharine L., Jakobsen, Lasse H., Villa, Diego, Smedby, Karin E., Savage, Kerry J., Eyre, Toby A., Cwynarski, Kate, Bishton, Mark J., Fox, Christopher P., Hawkes, Eliza A., Maurer, Matthew J., El-Galaly, Tarec C., Cheah, Chan Y., Bobillo, Sabela, Caporn, Paris L., Van Zyl, Joan, Klanova, Magdalena, Trněny, Marek, Puckrin, Robert, and Stewart, Douglas A.

Published
2023
Full Text
View/download PDF

65. FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Author

Maurer, Matthew J., Prochazka, Vit K, Flowers, Christopher R., Jakobsen, Lasse Hjort, Villa, Diego, Weibull, Caroline E., Cahn, Elliot J., Smith, Alexandra, Ghesquieres, Herve, Kridel, Robert, Gandhi, Maher, Cheah, Chan Y., Hawkes, Eliza, Seymour, John F., Freeman, Ciara L., Clausen, Michael Roost, Wahlin, Björn E, Friedberg, Jonathan W., Casulo, Carla, Habermann, Thomas M., Wang, Yucai, Nastoupil, Loretta J., Brown, Peter De Nully, Belada, David, Janíková , Andrea, Mocikova, Heidi, Fürst, Tomáš, Burack, Richard, Martin, Peter, Cohen, Jonathon B., Lossos, Izidore S., Kahl, Brad S., Link, Brian K., Smedby, Karin E., Sehn, Laurie H., Trneny, Marek, El-Galaly, Tarec Christoffer Christoffer, and Cerhan, James R.

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

67. Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry

Author

Baggio, Diva, primary, Wellard, Cameron, additional, Chung, Eliza, additional, Talaulikar, Dipti, additional, Keane, Colm, additional, Opat, Stephen, additional, Giri, Pratyush, additional, Minson, Adrian, additional, Cheah, Chan Yoon, additional, Armytage, Tasman, additional, Lee, Denise, additional, Chong, Geoffrey, additional, Johnston, Anna, additional, Cochrane, Tara, additional, Waters, Neil, additional, Hamad, Nada, additional, Wood, Erica M., additional, Hawkes, Eliza A., additional, Balendra, John, additional, Barraclough, Allison, additional, Berkahn, Leanne, additional, Bosco, Annmarie, additional, Carradice, Duncan, additional, Chuah, Hun, additional, Coyle, Luke, additional, Crassini, Kyle, additional, Kenealy, Melita, additional, Ku, Matthew, additional, Leung, Teresa, additional, Manos, Kate, additional, Morgan, Susan, additional, Mutsando, Howard, additional, Narayana, Manjunath, additional, Palfreymen, Emma, additional, Prince, Miles, additional, Ratnasingam, Sumita, additional, Simpson, Jock, additional, Trotman, Judith, additional, Viiala, Nicholas, additional, and Wight, Joel, additional

Published
2022
Full Text
View/download PDF

68. The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium

Author

Rodday, Angie Mae, primary, Parsons, Susan K., additional, Upshaw, Jenica N., additional, Friedberg, Jonathan W., additional, Gallamini, Andrea, additional, Hawkes, Eliza, additional, Hodgson, David, additional, Johnson, Peter, additional, Link, Brian K., additional, Mou, Eric, additional, Savage, Kerry J., additional, Zinzani, Pier Luigi, additional, Maurer, Matthew, additional, and Evens, Andrew M., additional

Published
2022
Full Text
View/download PDF

69. Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study

Author

Goh, Zhong, primary, Latimer, Maya, additional, Lewis, Katharine L., additional, Cheah, Chan Yoon, additional, Di Ciaccio, Pietro, additional, Cushion, Tania, additional, Hawkes, Eliza, additional, Harrop, Sean, additional, Ku, Matthew, additional, Campbell, Ashlea, additional, Hamad, Nada, additional, Wood, Erica M., additional, Chung, Eliza, additional, Chen, Pin-Yen, additional, and Cochrane, Tara, additional

Published
2022
Full Text
View/download PDF

71. Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Author

Opat, Stephen, primary, Tedeschi, Alessandra, additional, Hu, Bei, additional, Linton, Kim M., additional, McKay, Pamela, additional, Chan, Henry, additional, Jin, Jie, additional, Sun, Mingyuan, additional, Sobieraj-Teague, Magdalena, additional, Zinzani, Pier Luigi, additional, Browett, Peter J., additional, Ke, Xiaoyan, additional, Portell, Craig A., additional, Thieblemont, Catherine, additional, Ardeshna, Kirit, additional, Bijou, Fontanet, additional, Walker, Patricia, additional, Hawkes, Eliza, additional, Ho, Shir-Jing, additional, Zhou, Keshu, additional, Liang, Zhiyu, additional, Xu, Jianfeng, additional, Tankersley, Chris, additional, Delarue, Richard, additional, Co, Melannie, additional, and Trotman, Judith, additional

Published
2022
Full Text
View/download PDF

72. FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Author

Maurer, Matthew J., primary, Prochazka, Vit K, additional, Flowers, Christopher R., additional, Jakobsen, Lasse Hjort, additional, Villa, Diego, additional, Weibull, Caroline E., additional, Cahn, Elliot J., additional, Smith, Alexandra, additional, Ghesquieres, Herve, additional, Kridel, Robert, additional, Gandhi, Maher, additional, Cheah, Chan Y., additional, Hawkes, Eliza, additional, Seymour, John F., additional, Freeman, Ciara L., additional, Clausen, Michael Roost, additional, Wahlin, Björn E, additional, Friedberg, Jonathan W., additional, Casulo, Carla, additional, Habermann, Thomas M., additional, Wang, Yucai, additional, Nastoupil, Loretta J., additional, Brown, Peter De Nully, additional, Belada, David, additional, Janíková, Andrea, additional, Mocikova, Heidi, additional, Fürst, Tomáš, additional, Burack, Richard, additional, Martin, Peter, additional, Cohen, Jonathon B., additional, Lossos, Izidore S., additional, Kahl, Brad S., additional, Link, Brian K., additional, Smedby, Karin E., additional, Sehn, Laurie H., additional, Trneny, Marek, additional, El-Galaly, Tarec Christoffer Christoffer, additional, and Cerhan, James R., additional

Published
2022
Full Text
View/download PDF

73. Development and Validation of the advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Author

Rodday, Angie Mae, primary, Parsons, Susan K., additional, Friedberg, Jonathan W., additional, Gallamini, Andrea, additional, Hawkes, Eliza, additional, Hodgson, David C., additional, Johnson, Peter, additional, Link, Brian K., additional, Mou, Eric, additional, Savage, Kerry J., additional, Upshaw, Jenica, additional, Zinzani, Pier Luigi, additional, Maurer, Matthew J., additional, and Evens, Andrew M., additional

Published
2022
Full Text
View/download PDF

74. Diagnosis, management and follow up of peripheral T‐cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance

Author

Hapgood, Greg, primary, Latimer, Maya, additional, Lee, Sze Ting, additional, Kuss, Bryone, additional, Lade, Stephen, additional, Tobin, Joshua W. D., additional, Purtill, Duncan, additional, Campbell, Belinda A., additional, Prince, H. Miles, additional, Hawkes, Eliza A., additional, Shortt, Jake, additional, and Radeski, Dejan, additional

Published
2022
Full Text
View/download PDF

75. P010: Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium

Author

Parsons, Susan K., primary, Rodday, Angie Mae, additional, Friedberg, Jonathan W., additional, Gallamini, Andrea, additional, Hawkes, Eliza, additional, Hodgson, David, additional, Johnson, Peter, additional, Link, Brian, additional, Maurer, Matthew, additional, Nelson, Jason, additional, Savage, Kerry J., additional, Upshaw, Jenica, additional, Zinzani, Pier Luigi, additional, and Evens, Andrew M., additional

Published
2022
Full Text
View/download PDF

76. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

Author

Cunningham, David, Hawkes, Eliza A, Jack, Andrew, Qian, Wendi, Smith, Paul, Mouncey, Paul, Pocock, Christopher, Ardeshna, Kirit M, Radford, John A, McMillan, Andrew, Davies, John, Turner, Deborah, Kruger, Anton, Johnson, Peter, Gambell, Joanna, and Linch, David

Published
2013
Full Text
View/download PDF

77. Abstract A17: The immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma

Author

Gunawardana, Jay, primary, Law, Soi C., additional, Sabdia, Muhammed B., additional, Bednarska, Karolina, additional, Brosda, Sandra, additional, Zaharia, Andreea, additional, Tsang, Hennes, additional, de Long, Lilia M., additional, Burgess, Melinda, additional, Talaulikar, Dipti, additional, Lee, Justina N., additional, Jude, Emily, additional, Hawkes, Eliza A., additional, Jain, Sanjiv, additional, Nath, Karthik, additional, Gould, Clare, additional, Swain, Fiona, additional, Tobin, Joshua W. D., additional, Keane, Colm, additional, Birch, Simone, additional, Shanavas, Mohamed, additional, Snell, Cameron, additional, and Gandhi, Maher K., additional

Published
2022
Full Text
View/download PDF

78. A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer

Author

Sclafani, Francesco, Kim, Tae Y., Cunningham, David, Kim, Tae W., Tabernero, Josep, Schmoll, Hans J., Roh, Jae K., Kim, Sun Y., Park, Young S., Guren, Tormod K., Hawkes, Eliza, Clarke, Steven J., Ferry, David, Frödin, Jan-Erik, Ayers, Mark, Nebozhyn, Michael, Peckitt, Clare, Loboda, Andrey, Mauro, David J., and Watkins, David J.

Published
2015
Full Text
View/download PDF

88. Improving outcomes for patients with lymphoma: Design and development of the Australian Lymphoma and Related Diseases Registry

Author

Wood, Erica, primary, Anderson, Mary-Ann, additional, Berkahn, Leanne, additional, Cheah, Chan, additional, Dickinson, Michael, additional, Gandhi, Maher, additional, Giri, Pratyush, additional, Hawkes, Eliza, additional, Johnston, Anna, additional, Keane, Colm, additional, McQuilten, Zoe, additional, Mulligan, Stephen, additional, Talaulikar, Dipti, additional, Opat, Stephen, additional, Trotman, Judith, additional, Williams, Janne, additional, Armytage, Tasman, additional, Barraclough, Allison, additional, Carradice, Duncan, additional, Chong, Geoffrey, additional, Cochrane, Tara, additional, Hamad, Nada, additional, Ku, Matthew, additional, Lee, Denise, additional, Morgan, Susan, additional, Mutsando, Howard, additional, Narayana, Manjunath, additional, Prince, Miles, additional, Ratnasingam, Sumita, additional, Wight, Joel, additional, Badoux, Xavier, additional, Cull, Gavin, additional, Kuss, Byrone, additional, Marlton, Paula, additional, Tam, Constantine, additional, Casan, Joshua, additional, Cushion, Tania, additional, Tedjaseputra, Aditya, additional, Birch, Simone, additional, Brown, Christina, additional, Ellis, David, additional, Harvey, Yasmin, additional, Hitchins, Sam, additional, Jain, Sanjiv, additional, Jessup, Peter, additional, Juneja, Surendar, additional, Kearney, Daniel, additional, Kumar, Beena, additional, Lade, Stephen, additional, Lee, Kenneth, additional, Leslie, Connull, additional, Long, Eileen, additional, Morey, Adrienne, additional, Nath, Lakshmi, additional, Norris, Debra, additional, Parker, Andrew, additional, Parry, Jeremy, additional, Chen, Fiona Pin-Yen, additional, Chung, Eliza, additional, Morison, Jessica, additional, Rowsell, Luke, additional, George, Gayathri St, additional, Thu, Christianto, additional, Waters, Neil, additional, Wellard, Cameron, additional, and Zheng, Michelle, additional

Published
2022
Full Text
View/download PDF

89. Cancer-related Cognitive Impairment in Patients With Newly Diagnosed Aggressive Lymphoma Undergoing Standard Chemotherapy: a Longitudinal Feasibility Study

Author

Gates, Priscilla, primary, Krishnasamy, Meinir, additional, Wilson, Carlene, additional, Hawkes, Eliza A, additional, Dore, Vincent, additional, Perchyonok, Yuliya, additional, Rowe, Christopher C, additional, Walker, Adam K, additional, Vardy, Janette L, additional, de Ruiter, Michiel, additional, Cushion, Tania, additional, Dhillon, Haryana M, additional, and Gough, Karla, additional

Published
2022
Full Text
View/download PDF

90. Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.

Author

Baggio, Diva, Wellard, Cameron, Chung, Eliza, Talaulikar, Dipti, Keane, Colm, Opat, Stephen, Giri, Pratyush, Minson, Adrian, Cheah, Chan Yoon, Armytage, Tasman, Lee, Denise, Chong, Geoffrey, Johnston, Anna, Cochrane, Tara, Waters, Neil, Hamad, Nada, Wood, Erica M., Hawkes, Eliza A., Balendra Dr, John, and Barraclough Dr, Allison

Subjects
MANTLE cell lymphoma, BRUTON tyrosine kinase, MEDICAL registries, PATIENTS' attitudes, LYMPHOMAS
Abstract

Bruton's tyrosine kinase inhibitors (BTKi) have an established role in the management of patients with relapsed/refractory mantle cell lymphoma (MCL). However, scant data exist on outcomes of patients ineligible for clinical trials testing these therapies. We describe a contemporary cohort of relapsed/refractory MCL patients from the Australasian Lymphoma and Related Diseases Registry treated with ibrutinib December 2014 until July 2018, to determine the proportion potentially eligible for original trials, reasons for ineligibility and survival outcomes. Of 44 patients, 41% met one or more exclusion criteria from previous phase II/III MCL BTKi studies. Median progression-free and overall survival were 13.7 months (95% CI 6.2–28.1) and 15.6 months (95% CI 10.8–29.6) respectively and were shorter in patients excluded from clinical trials based on ECOG ≥2. Ibrutinib has demonstrable clinical effectiveness in a population enriched for unfit and trial-ineligible patients, and a need for more inclusive enrollment criteria in future BTKi studies is highlighted. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

91. The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial

Author

Chavez, Julio C., primary, Goldschmidt, Neta, additional, Samaniego, Felipe, additional, Wrobel, Tomasz, additional, Cavallo, Federica, additional, Fonseca, Gustavo, additional, Yoon, Sung-Soo, additional, Drgona, Lubos, additional, Hawkes, Eliza, additional, Levi, Itai, additional, Miskin, Hari P., additional, Sportelli, Peter, additional, O'Connor, Owen A., additional, Fowler, Nathan H., additional, and Zinzani, Pier Luigi, additional

Published
2021
Full Text
View/download PDF

92. The NLPHL Tumor Microenvironment Is Markedly Enriched in the Tigit and PD-1 Signalling Axes Compared to Classical Hodgkin Lymphoma

Author

Gunawardana, Jay, primary, Sabdia, Muhammed B., additional, Bednarska, Karolina, additional, Law, Soi C., additional, Brosda, Sandra, additional, Tsang, Hennes, additional, De Long, Lilia Merida, additional, Zaharia, Andreea, additional, Lee, Justina, additional, Jude, Emily, additional, Hawkes, Eliza, additional, Nath, Karthik, additional, Gould, Clare, additional, Burgess, Melinda Lea, additional, Swain, Fiona, additional, Tobin, Joshua W.D., additional, Keane, Colm, additional, Birch, Simone, additional, Talaulikar, Dipti, additional, Jain, Sanjiv, additional, Shanavas, Mohamed, additional, Snell, Cameron, additional, and Gandhi, Maher, additional

Published
2021
Full Text
View/download PDF

93. Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA)

Author

Tatarczuch, Maciej, primary, Lewis, Katharine Louise, additional, Gunjur, Ashray, additional, Shaw, Briony, additional, Poon, Michelle, additional, Paul, Erin, additional, Ku, Matthew, additional, Wong, Mark, additional, Beekman, Ashley, additional, Krigstein, Michael, additional, Di Ciaccio, Pietro R, additional, Wight, Joel, additional, Coombes, Caitlin, additional, Gilbertson, Michael, additional, Tey, Amanda, additional, Shortt, Jake, additional, Nagarajan, Chandramouli, additional, Latimer, Maya, additional, Talaulikar, Dipti, additional, Hamad, Nada, additional, Ratnasingam, Sumita, additional, Cochrane, Tara, additional, Hawkes, Eliza, additional, Cheah, Chan Yoon, additional, Opat, Stephen, additional, and Gregory, Gareth P, additional

Published
2021
Full Text
View/download PDF

94. High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients

Author

Lewis, Katharine Louise, primary, Jakobsen, Lasse H., additional, Villa, Diego, additional, Bobillo, Sabela, additional, Ekstroem Smedby, Karin, additional, Savage, Kerry J., additional, Eyre, Toby A., additional, Cwynarski, Kate, additional, Caporn, Paris L, additional, Zyl, Joan Van, additional, Klanova, Magdalena, additional, Trněný, Marek, additional, Puckrin, Robert, additional, Stewart, Douglas A., additional, Bishton, Mark J, additional, Fox, Christopher P., additional, Tun, Aung M, additional, Thanarajasingam, Gita, additional, Djebbari, Faouzi, additional, Joffe, Erel, additional, Eloranta, Sandra, additional, Harrysson, Sara, additional, Sehn, Laurie H., additional, Maliske, Seth M, additional, Poonsombudlert, Kittika, additional, Guo, Xiao, additional, Hapgood, Greg, additional, Manos, Kate, additional, Hawkes, Eliza, additional, Khwaja, Jahanzaib, additional, Minson, Adrian, additional, Dickinson, Michael, additional, Øvlisen, Andreas Kiesbye, additional, Gregory, Gareth P, additional, Gilbertson, Michael, additional, Streit, Isaac T, additional, Scott, Hamish W, additional, Ku, Matthew, additional, de Mel, Sanjay, additional, Yong, Kar Ying, additional, Xin, Liu, additional, Mokoonlall, Mridula, additional, Talaulikar, Dipti, additional, McVilly, Nicholas L, additional, Johnston, Anna, additional, Brunner, Matthew J, additional, Pophali, Priyanka A, additional, Maurer, Matthew J., additional, El-Galaly, Tarec Christoffer, additional, and Cheah, Chan Yoon, additional

Published
2021
Full Text
View/download PDF

95. Avenue - Avelumab in the Frontline Treatment of Advanced Classic Hodgkin Lymphoma - a Window Study

Author

Booth, Stephen, primary, Hawkes, Eliza, additional, Kirkwood, Amy A, additional, Barrington, Sally F, additional, Medd, Patrick G., additional, McKay, Pamela, additional, Pettengell, Ruth, additional, Iyengar, Sunil, additional, Miall, Fiona, additional, Radford, John, additional, Burton, Cathy, additional, Sud, Amit, additional, Shah, Nimish, additional, Scott, Andrew M, additional, Ardavan, Arzhang, additional, Northend, Michael, additional, Clifton-Hadley, Laura, additional, Jenner, Richard, additional, and Collins, Graham P., additional

Published
2021
Full Text
View/download PDF

96. Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Author

Strati, Paolo, primary, Hawkes, Eliza, additional, Ghosh, Nilanjan, additional, Tuscano, Joseph M., additional, Chu, Quincy, additional, Anderson, Mary Ann, additional, Patel, Amar, additional, Burgess, Michael R., additional, Hege, Kristen, additional, Chhagan, Sapna, additional, Boyanapalli, Sarandeep, additional, Day, Tracey, additional, Shen, Frank, additional, and Mehta, Amitkumar, additional

Published
2021
Full Text
View/download PDF

97. Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium

Author

Maurer, Matthew J., primary, Prochazka, Vit K, additional, Flowers, Christopher R., additional, Jakobsen, Lasse H., additional, Villa, Diego, additional, Weibull, Caroline, additional, Cahn, Elliot J., additional, Ghesquieres, Herve, additional, Kridel, Robert, additional, Gandhi, Maher, additional, Cheah, Chan Yoon, additional, Hawkes, Eliza, additional, Seymour, John F., additional, Freeman, Ciara L., additional, Clausen, Michael Roost, additional, Wahlin, Björn, additional, Link, Brian K., additional, Ekstroem Smedby, Karin, additional, Sehn, Laurie H., additional, Trněný, Marek, additional, El-Galaly, Tarec Christoffer, additional, and Cerhan, James R., additional

Published
2021
Full Text
View/download PDF

98. A Window Study of Acalabrutinib Plus Rituximab Followed By R-Dhaox (rituximab, dexamethasone, cytarabine, oxaliplatin) and Autologous Stem Cell Transplant (ASCT) in Fit Mantle Cell Lymphoma (MCL): The Australasian Leukaemia & Lymphoma Group (ALLG) NHL33 Wamm Trial

Author

Hawkes, Eliza, primary, Agrawal, Shivam, additional, Lee, Sze-Ting, additional, Wight, Joel, additional, Hapgood, Greg, additional, Armytage, Tasman, additional, Wong Doo, Nicole, additional, Cochrane, Tara, additional, Cheah, Chan-Yoon, additional, Bilmon, Ian, additional, Ku, Matthew, additional, Opat, Stephen, additional, Devitt, Bianca, additional, Fong, Chun Yew, additional, Fancourt, Tineke, additional, Walia, Mannu, additional, Nkhoma, Gloria, additional, and Barraclough, Allison, additional

Published
2021
Full Text
View/download PDF

99. Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study

Author

Verner, Emma, primary, Johnston, Amanda, additional, Pati, Nalini, additional, Hawkes, Eliza, additional, Lee, Hui-Peng, additional, Cochrane, Tara, additional, Cheah, Chan-Yoon, additional, Filshie, Robin J, additional, Purtill, Duncan, additional, Sia, Hanlon, additional, Enjeti, Anoop Kumar, additional, Brown, Christina, additional, Murphy, Nicholas E., additional, Curnow, Jennifer, additional, Lee, Kenneth, additional, Walia, Mannu, additional, Butcher, Belinda, additional, and Trotman, Judith, additional

Published
2021
Full Text
View/download PDF

100. Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance

Author

Boyle, Stephen, primary, Tobin, Joshua W. D., additional, Perram, Jacinta, additional, Hamad, Nada, additional, Gullapalli, Veena, additional, Barraclough, Allison, additional, Singaraveloo, Lydia, additional, Han, Min-Hi, additional, Blennerhassett, Richard, additional, Nelson, Niles, additional, Johnston, Anna M., additional, Talaulikar, Dipti, additional, Karpe, Krishna, additional, Bhattacharyya, Abir, additional, Cheah, Chan Yoon, additional, Subramoniapillai, Elango, additional, Bokhari, Waqas, additional, Lee, Cindy, additional, Hawkes, Eliza A., additional, Jabbour, Andrew, additional, Strasser, Simone I., additional, Chadban, Steven J., additional, Brown, Christina, additional, Mollee, Peter, additional, and Hapgood, Greg, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results